BIIB vs PTCT: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of September 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: BIIB is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BIIB and PTCT share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BIIB and PTCT exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Biogen is a Cambridge, Massachusetts biotechnology company built on neuroscience. Its historic core is multiple sclerosis (Tysabri, Tecfidera, Vumerity), and it co-developed the spinal muscular atrophy drug Spinraza with Ionis. Its growth story now centers on Leqembi, the Alzheimer's antibody it markets with partner Eisai, alongside newer rare-disease products Skyclarys (Friedreich's ataxia) and Qalsody (ALS). In 2026 it closed the roughly $5.6 billion acquisition of Apellis Pharmaceuticals, adding the retinal drug Syfovre for geographic atrophy and Empaveli for rare blood and kidney diseases.

Full BIIB guide

PTC Therapeutics is a New Jersey-based biopharmaceutical company focused on rare and neurological diseases. It sells a portfolio of approved medicines including Sephience (sepiapterin) for phenylketonuria (PKU), Translarna (ataluren) and Emflaza (deflazacort) for Duchenne muscular dystrophy, and Kebilidi, a gene therapy for AADC deficiency. It also earns royalties on Evrysdi (risdiplam), the Roche/Genentech spinal muscular atrophy drug that PTC helped discover, and runs a pipeline led by votoplam, a splicing modifier partnered with Novartis for Huntington's disease.

Full PTCT guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• BIIB drivers: Leqembi Alzheimer's ramp; Rare-disease and new-product portfolio.
• PTCT drivers: Sephience (PKU) launch ramp; Evrysdi royalty and cash generation.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The legacy MS business (Tecfidera, Tysabri) continues to decline against generics and biosimilars, and full-year 2026 total revenue is guided down a mid-single-digit percentage. For PTCT, the largest risk is legacy-franchise erosion: Translarna is sold in Europe without a valid marketing authorization and faces removal, while Emflaza has lost exclusivity, so a meaningful revenue base could disappear.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick BIIB if you believe its drivers more; PTCT if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BIIB and PTCT guides.

BIIB. Biogen trades at a low double-digit forward earnings multiple, well below the drug-manufacturer industry median, reflecting a shrinking legacy base and turnaround uncertainty. Q1 2026 earnings beat expectations on cost discipline and Leqembi momentum, but management still guides full-year revenue down a mid-single-digit percentage. The valuation prices in doubt that new launches will outrun legacy erosion.

PTCT. PTCT trades at a mid-single-digit multiple of revenue, typical for a rare-disease specialist still working toward consistent GAAP profitability. Because much of the near-term growth rides on the Sephience launch curve, the valuation is sensitive to launch trajectory and legacy-revenue durability rather than a simple earnings multiple. The heavy royalty-monetization liabilities mean enterprise value differs materially from market cap.

Headline figures (approximate, MAY 2026): BIIB shows revenue (ttm) ~$9.7B, q1 2026 revenue ~$2.5B (up ~2% YoY), q1 2026 non-gaap eps ~$3.57, market cap ~$29B; PTCT shows market cap ~$6.5 billion, revenue (ttm) ~$1.0 billion, 2026 total revenue guidance ~$1.08-$1.18 billion, 2026 product revenue guidance ~$750-$850 million.

BIIB and PTCT are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined BIIB and PTCT exposure against your real portfolio. It is not an investment adviser.